Benitec Biopharma Inc.
BNTC
$11.50
-$0.18-1.54%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | 100.00% | 97.14% |
| Gross Profit | -- | -- | -- | -100.00% | -98.19% |
| SG&A Expenses | 181.72% | 286.47% | 262.21% | 119.32% | 88.15% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 92.29% | 114.09% | 95.46% | 50.39% | 20.83% |
| Operating Income | -92.29% | -114.09% | -95.46% | -50.44% | -21.17% |
| Income Before Tax | -96.12% | -111.06% | -84.41% | -32.24% | -8.25% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -96.12% | -111.06% | -84.41% | -32.24% | -8.25% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -96.12% | -111.06% | -84.41% | -32.24% | -8.25% |
| EBIT | -92.29% | -114.09% | -95.46% | -50.44% | -21.17% |
| EBITDA | -92.75% | -114.74% | -95.93% | -50.65% | -21.26% |
| EPS Basic | -29.64% | 65.80% | 82.43% | 90.14% | 92.36% |
| Normalized Basic EPS | -26.60% | 65.16% | 81.20% | 89.56% | 91.97% |
| EPS Diluted | -29.64% | 65.80% | 82.43% | 90.14% | 92.36% |
| Normalized Diluted EPS | -26.60% | 65.16% | 81.20% | 89.56% | 91.97% |
| Average Basic Shares Outstanding | 53.09% | 112.60% | 196.66% | 425.40% | 1,261.44% |
| Average Diluted Shares Outstanding | 53.09% | 112.60% | 196.66% | 425.40% | 1,261.44% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |